These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 2942753)
21. Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon. Wise RA; Wigley F J Rheumatol; 1994 Jan; 21(1):80-3. PubMed ID: 8151594 [TBL] [Abstract][Full Text] [Related]
22. Triiodothyronine treatment for Raynaud's phenomenon: a controlled trial. Dessein PH; Morrison RC; Lamparelli RD; van der Merwe CA J Rheumatol; 1990 Aug; 17(8):1025-8. PubMed ID: 2213778 [TBL] [Abstract][Full Text] [Related]
23. Raynaud's disease: a new therapeutic approach with a 5-HT2 receptors blocker. Allegra C; Tonelli V; Bonifacio M; Mari A; Assogna G Boll Chim Farm; 1985 Oct; 124(10):121S-124S. PubMed ID: 2935173 [No Abstract] [Full Text] [Related]
24. Isosorbide dinitrate ointment in Raynaud's disease. Diehm C; Müller-Bühl U; Mörl H Z Kardiol; 1983; 72 Suppl 3():185-7. PubMed ID: 6364591 [TBL] [Abstract][Full Text] [Related]
25. Digital blood pressure and flow measurements in patients with primary Raynaud's phenomenon. van de Wal HJ; Wijn PF; Hoppenbrouwers MW; Skotnicki SH Angiology; 1986 Mar; 37(3 Pt 1):185-97. PubMed ID: 3706820 [TBL] [Abstract][Full Text] [Related]
26. [Calcium antagonists for the treatment of Raynaud's phenomenon]. Müller-Bühl U; Diehm C; Scheuermann W; Mörl H Dtsch Med Wochenschr; 1983 Nov; 108(47):1795-7. PubMed ID: 6357692 [TBL] [Abstract][Full Text] [Related]
27. Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud's phenomenon. Brouwer RM; Wenting GJ; Man in't Veld AJ; Schalekamp MA J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S26-31. PubMed ID: 2446064 [TBL] [Abstract][Full Text] [Related]
28. Ketanserin in the treatment of mild hypertension in elderly patients: preliminary results of a controlled double-blind trial. Dona G; Ribeiro A; Tammaro AE J Hypertens Suppl; 1986 Apr; 4(1):S89-90. PubMed ID: 2939220 [TBL] [Abstract][Full Text] [Related]
29. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Chung L; Shapiro L; Fiorentino D; Baron M; Shanahan J; Sule S; Hsu V; Rothfield N; Steen V; Martin RW; Smith E; Mayes M; Simms R; Pope J; Kahaleh B; Csuka ME; Gruber B; Collier D; Sweiss N; Gilbert A; Dechow FJ; Gregory J; Wigley FM Arthritis Rheum; 2009 Mar; 60(3):870-7. PubMed ID: 19248104 [TBL] [Abstract][Full Text] [Related]
30. The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon. Dormandy JA; Berent A; Downes SJ Eur J Vasc Surg; 1988 Dec; 2(6):371-5. PubMed ID: 3075559 [TBL] [Abstract][Full Text] [Related]
31. A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome. Rustin MH; Grimes SM; Kovacs IB; Cooke ED; Bowcock SA; Sowemimo-Coker SO; Turner P; Kirby JD Eur J Clin Pharmacol; 1984; 27(1):61-5. PubMed ID: 6386490 [TBL] [Abstract][Full Text] [Related]
32. Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin. Stranden E; Roald OK; Krohg K Br Med J (Clin Res Ed); 1982 Oct; 285(6348):1069-71. PubMed ID: 6812750 [TBL] [Abstract][Full Text] [Related]
33. [Comparative study of misoprostol and nifedipine in the treatment of Raynaud's phenomenon secondary to systemic diseases. Hemodynamic assessment with Doppler duplex]. Varela-Aguilar JM; Sánchez-Román J; Talegón Meléndez A; Castillo Palma MJ Rev Clin Esp; 1997 Feb; 197(2):77-83. PubMed ID: 9213861 [TBL] [Abstract][Full Text] [Related]
34. [Treatment of Raynaud's syndrome with calcium entry blockers]. Shcherbakov AB; Guseva NG; Mach ES Ter Arkh; 1987; 59(4):89-92. PubMed ID: 3296288 [TBL] [Abstract][Full Text] [Related]
35. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma. Engelhart M Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193 [TBL] [Abstract][Full Text] [Related]
36. Ketanserin, hypertension, and chronic alcoholism: double-blind study in forty patients. de Lorenzo A; Ceccanti M; Assogna G; Romeo M; Cavaleri G; Attilia ML Int J Clin Pharmacol Res; 1988; 8(5):321-5. PubMed ID: 3068159 [TBL] [Abstract][Full Text] [Related]
37. Does serotonin receptor blockade have a therapeutic effect in Raynaud's phenomenon? Brouwer RM; Wenting GJ; Visser W; Schalekamp MA Vasa Suppl; 1987; 18():64-7. PubMed ID: 3299817 [No Abstract] [Full Text] [Related]
38. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476 [TBL] [Abstract][Full Text] [Related]
39. Cold hands after exposure to arsenic or vibrating tools: effects of ketanserin on finger blood pressure and skin temperature. Lagerkvist BE; Linderholm H Acta Pharmacol Toxicol (Copenh); 1986 May; 58(5):327-32. PubMed ID: 2943135 [TBL] [Abstract][Full Text] [Related]